Years Active: 2025
Title: Leila Sevigny: Innovator in Immunology
Introduction
Leila Sevigny is a prominent inventor based in Cambridge, MA (US). She has made significant contributions to the field of immunology, particularly in the development of multifunctional binding proteins. Her work focuses on innovative solutions for treating proliferative disorders, including multiple myeloma.
Latest Patents
Leila Sevigny holds a patent for "Natural killer (NK) cell engagers binding to NKp46 and BCMA variants with Fc-engineering." This patent describes multifunctional binding proteins that comprise a first and a second antigen binding domain (ABD) and all or part of an immunoglobulin Fc region or variant thereof. The first ABD specifically binds to human BCMA, while the second ABD binds to human NKp46. Additionally, the immunoglobulin Fc region binds to a human Fc-γ receptor. This invention has potential applications in the treatment or prevention of proliferative disorders, including multiple myeloma (MM).
Career Highlights
Throughout her career, Leila Sevigny has demonstrated a commitment to advancing medical science through her innovative research. Her work has not only contributed to the understanding of immune responses but also paved the way for new therapeutic strategies.
Collaborations
Leila has collaborated with notable colleagues, including Nicolas Gourdin and Laurent Gauthier. These partnerships have enhanced her research and contributed to the successful development of her patented technologies.
Conclusion
Leila Sevigny is a trailblazer in the field of immunology, with a focus on developing innovative solutions for serious health conditions. Her contributions, particularly through her patent, highlight her role as a key inventor in advancing medical science.